Astera Labs ($ALAB) CFO Receives Equity Compensation Grant
Astera Labs, Inc.
Subscribe to track ALAB
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Astera Labs ($ALAB) CFO Receives Equity Compensation Grant
Company: Astera Labs, Inc. (ALAB) Form: 4 | Filed: 2026/02/10 Significance: Low
Insider: Tate Michael Truett Title: Chief Financial Officer | Relationship: Officer
Transaction: • Type: Grant (RSU Award) • Shares: 11,787 • Price: $0.00 • Value: $0 • Owned After: 654,365 (Direct & Indirect)
Key Insight: This is a routine equity compensation grant to the CFO, representing a negligible 0.007% of total shares outstanding.
Market Context: Such grants are standard practice for executive compensation in the tech industry to align insider interests with shareholder value over the long term.
Comprehensive Analysis
SEC Filing Analysis: Astera Labs, Inc. (ALAB)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Chief Financial Officer of Astera Labs received a routine grant of Restricted Stock Units (RSUs) as part of their compensation package.
- Market Impact: Neutral. This transaction is a non-cash, pre-planned compensation event and does not reflect new market sentiment from the insider.
Company Information
| Field | Value |
|---|---|
| Company | Astera Labs, Inc. |
| Ticker Symbol | ALAB |
| CIK | 0001736297 |
| Industry | Semiconductors & Related Devices |
Insider Information
| Field | Value |
|---|---|
| Name | Tate Michael Truett |
| CIK | 0001399546 |
| Title/Position | Chief Financial Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2026-02-06 |
| Transaction Code | A (Award) |
| Security Type | Common Stock (via RSUs) |
| Shares Involved | 11,787 |
| Price Per Share | $0.00 |
| Total Value | $0 |
| Shares Owned After | 204,084 (Directly) & 450,281 (Indirectly) |
| Ownership Type | Direct & Indirect |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0 |
| % of Market Cap | 0.0% |
| Shares Transacted | 11,787 |
| % of Shares Outstanding | 0.007% |
| Post-Transaction Ownership | 654,365 shares (0.387% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The transaction has no monetary value and is therefore immaterial against Astera Labs' $28.69 billion market capitalization.
- Ownership Concentration: The CFO's total post-transaction ownership remains modest at 0.387% of shares outstanding, indicating no significant concentration of control.
- Dilution Impact: The issuance of 11,787 shares represents a minimal dilution of 0.007% to existing shareholders, which is a routine and expected part of corporate compensation strategies.
- Transaction Significance: The significance is low. This is a standard, non-market transaction intended as long-term incentive compensation, not an active investment decision by the insider.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Equity grants are a common form of executive compensation and are not indicative of an insider's short-term outlook on the company's stock. The market generally does not react to such filings.
Volume & Sentiment
- Expected Volume Impact: None. This was not an open-market transaction and does not affect trading volume.
- Sentiment Indicator: Neutral. The filing confirms standard corporate governance practices regarding executive pay.
Additional Context
Transaction Notes
- Special Circumstances: The filing notes that these shares are Restricted Stock Units (RSUs) granted under the company's 2024 Stock Option and Incentive Plan. The RSUs vest over time, with 25% vesting in one year and the remainder quarterly thereafter, contingent on continued service. This structure is designed to retain key executives.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
